Roche to share important oncology data at European Cancer Congress (ECC) including information on he

dfd24

from http://www.biosciencetechnology.com/news/2013/09/roche-share-important-oncology-data-european-cancer-congress-ecc#.UkKMfijWFyM

Kadcyla:

• Abstract #15: LATE BREAKING ABSTRACT T-DM1 for HER2-positive metastatic breast cancer (MBC): Primary results from TH3RESA, a phase 3 study of T-DM1 vs treatment of physician's choice. ECC media briefing September 28. Proffered papers session, Saturday, September 28, 13:03 – 13:15 in Hall 7.1

Herceptin SC:

• Abstract #1759: Reasons for patients' preferences for subcutaneous or intravenous trastuzumab in the PrefHer study. Poster session, Saturday, September 28, 09:30 – 16:30 in Hall 4

callerid

Kadcyla & Herceptin SC

Very interesting. Do you know where these will be published.

Thanks

dfd24

callerid said:

Kadcyla & Herceptin SC

Very interesting. Do you know where these will be published.

Thanks

European Cancer Congress (ECC)

i think if you look  up

European Cancer Congress (ECC) in the coming month they should talk about the results. also if you put in a google alert  for Kadcyla and Herceptin SC then any information would be emailed to your gmail mail account ( you can sign up for one if you don't have one ). also looking up the TH3RESA STUDY should bring results.best,

danièle

goty2001

dfd24 said:

European Cancer Congress (ECC)

i think if you look  up

European Cancer Congress (ECC) in the coming month they should talk about the results. also if you put in a google alert  for Kadcyla and Herceptin SC then any information would be emailed to your gmail mail account ( you can sign up for one if you don't have one ). also looking up the TH3RESA STUDY should bring results.best,

danièle

Good information

Thanks for posting.  Hope it's good data.

 

Everybody should ensure they get tested for HER2+